Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, has appointed Daniel Keefe as Commercial Director, Western U.S. The appointment comes as the company reports triple-digit growth in utilization of its Nociscan platform, reflecting increasing demand for noninvasive diagnostic solutions in spine care.
Keefe will lead commercial efforts across the Western region, building on Aclarion’s existing footprint and supporting continued adoption of Nociscan. The company has established a growing presence across the Western U.S., with engagement spanning both academic institutions and high-volume private practice spine centers, supported by strong volume growth. His appointment reflects Aclarion’s focus on expanding this momentum and deepening adoption in a key strategic region.
“Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies,” said Brent Ness, Chief Executive Officer of Aclarion. “His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan.”
Keefe joins Aclarion with more than 20 years of experience in medical device and healthcare technology sales, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, he served as Regional Sales Manager at Centinel Spine, where he consistently exceeded performance targets and delivered significant year-over-year growth across the Northern California region. Throughout his career, Keefe has demonstrated success in building strategic relationships with surgeons and hospital leadership, launching new technologies, and expanding market presence in competitive environments.
“I’m excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community,” said Keefe. “The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated. I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice.”
An estimated 266 million people worldwide live with chronic low back pain, making it one of the most pervasive health challenges. Aclarion’s Nociscan solution is the first evidence-supported, cloud-based platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
For more information about Nociscan, visit www.aclarion.com. To find a Nociscan center, view the site map here.
